Cellular Biomedicine Group Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Progress
- Executed Licensing and Collaboration Agreement with Novartis
- Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat Solid Tumors
- Expanded Research and Development with new center in Gaithersburg, Maryland
- Added talents in clinical and medical leadership and investor relations to improve communications with institutional investors
- Dr. Stephan Grupp joined CBMG Scientific Advisory Board
- 2 significant investments into the Company
- Fortified balance sheet with $52.8 million cash at year end
SHANGHAI and NEW YORK, Feb. 19, 2019 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (CBMG or the Company), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018.
"2018 was a stellar year for CBMG. The licensing and collaboration agreement with Novartis reaffirmed our position in the cell therapy industry. We continue to focus on our goal to bring safe and effective cell-therapies to patients with unmet medical needs. We are diligently advancing our pipeline in 2019 and expanding into solid tumors with α-fetoprotein T-cell receptors (AFP-TCR) and tumor infiltrating lymphocyte (TIL) technologies. We have a robust pipeline that spans across 8 different modalities," said Tony Liu, CEO of CBMG. "We expanded our senior leadership team with the hiring of Dr. Michael Humphries, a seasoned drug developer from Novartis, and Derrick Li, former Managing Director in the healthcare investment banking group at B. Riley FBR. We were privileged to have Dr. Stephan Grupp join our Scientific Advisory Board. 2019 will be a busy year. In January we announced the initiation of our B-cell maturation antigen (BCMA) clinical trial. Besides the AFP-TCR and TIL solid tumor platform, in 2019 we plan to initiate clinical development for CAR-T programs for CD22, CD20 and NKG2D for hematological cancers, and AFP TCR-T for metastatic HCC."
Recent Highlights
COLLABORATION AND LICENSING AGREEMENT WITH NOVARTIS ON KYMRIAH® – We signed a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China (*Kymriah® is a registered trademark of Novartis AG). CBMG licensed certain proprietary technology to Novartis for global use.
- NCI PATENT LICENSE FOR NEXT GENERATION TIL TECHNOLOGY TO TREAT SOLID TUMORS – We have licensed patents from the National Cancer Institute (NCI), an institute of the National Institutes of Health (NIH), to develop, manufacture and commercialize next generation neoantigen-reactive TIL technology to treat solid tumors.
- OPENING OF GLOBAL RESEARCH AND DEVELOPMENT CENTER IN MARYLAND – We expanded our research and development resources with a new center in Gaithersburg, Maryland.
- POSITIVE PHASE I CLINICAL DATA ON ALLOJOIN® FOR KNEE OSTEOARTHRITIS (KOA) – In March 2018, we released promising results of our Phase I Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC) clinical trial for Knee Osteoarthritis. The 48-week analysis of study data of 22 patients demonstrated AlloJoin®, off-the-shelf allogeneic stem cell therapy for KOA, to have good safety tolerance and early signs of efficacy in preventing cartilage deterioration. The total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores (consisting of pain, stiffness and function scores of joints) as a primary end point showed a significant improvement at 12 weeks post AlloJoin® cell therapy and continued improvement at 48 weeks. The secondary evaluation end point, the data of 3D spoiled gradient-recalled echo (SPGR) quantitative magnetic resonance imaging (MRI) for whole knee cartilage volume at 48 weeks showed an increased tendency when compared with that at baseline 0 weeks, and as compared with normal cartilage deterioration as a result of aging. Using this clinical package, our IND submission with China's National Medical Products Administration (NMPA) recently received unprecedented approval to move forward with a Phase II clinical trial in off-the-shelf allogeneic stem cell therapy for KOA.
- STRATEGIC INVESTMENTS – We received two investments from:
- (a) Sailing Capital, a global private equity firm focused on China cross-border in disruptive global companies in the healthcare, technology and consumer sectors, invested $30.6 million; and
- (b) Novartis, as part of our collaboration, includes a $40 million equity investment in CBMG.
- FORTIFIED OUR CLINICAL AND MEDICAL LEADERSHIP – Dr. Humphries, a seasoned pharmaceutical executive with over 28 year of experience in clinical research, regulatory affairs, drug safety and medical affairs in China in all therapy areas, joined us from Novartis China. Dr. Humphries has contributed to a total of 56 New Drug Application (NDA) approvals in China. He has held adjunct professor teaching positions at both Hong Kong University and the Chinese University of Hong Kong in internal medicine. Dr. Humphries previously held a number of leadership and technical positions with Novartis China, GlaxoSmithKline – GSK China/Hong Kong, and Roche Pharmaceuticals.
- REVAMPED & AUGMENTED INVESTOR RELATIONS, FOR INCREASED VISIBILITY WITH INSTITUTIONAL INVESTORS – Mr. Derrick Li, a seasoned healthcare investment banker joined CBMG from B. Riley FBR, where he served as Managing Director in its healthcare investment-banking group. Mr. Li previously was a Co-Founder and Managing Director at TPP Healthcare and was an Equity Analyst at the Royce Funds. Mr. Li has substantially improved and institutionalized our communications with the Street.
- APPOINTMENT OF DR. STEPHAN GRUPP TO SCIENTIFIC ADVISORY BOARD –Dr. Grupp, a Professor of Pediatrics and the University of Pennsylvania Perelman School of Medicine, is a CAR-T pioneer and pediatric oncologist. Dr. Grupp is the Chief of Section – Cellular Therapy and Transplant in the Oncology Division at The Children's Hospital of Philadelphia (CHOP) where he has researched and led clinical trials of CD19 directed CAR-T cell therapy for children with acute lymphoblastic leukemia (ALL). Dr. Grupp also serves as Medical Director of the Stem Cell Laboratory at CHOP and has been an attending physician and oncology researcher at CHOP since 1996.
2019 Anticipated Immuno-Oncology Key Milestones
- Initiation of an investigator-led Phase I clinical study of CD22 targeting relapsed CD19 ALL patients
- Initiation of an investigator-led Phase I clinical study of CD20 targeting relapsed CD19 Non-Hodgkin lymphoma (NHL) patients
- Initiation of an investigator-led Phase I clinical study of NKG2D targeting acute myeloid leukemia (AML) patients
- Initiation of a Phase I clinical study of AFP-TCR for Hepatocellular carcinoma (HCC) in the U.S. and in China
- Initiation of a Phase I clinical study of TIL in Non-small-cell lung carcinoma (NSCLC) in the U.S. and in China
- Presentation of BCMA clinical data from the ongoing BCMA clinical study in patients with MM by end of 2019
Fourth Quarter and Full Year 2018 Financial Results
- Cash Position: Cash, cash equivalents and marketable securities as of December 31, 2018 were $52.8 million, compared to $21.6 million as of December 31, 2017, an increase of $31.2 million, which was primarily driven by the Sailing Capital and Novartis investments.
- Revenues: We received de minims incidental fees for service while focusing our resources on our drug development activities.
- R&D Expenses: Research and development expenses were $24.2 million for 2018 as compared to $14.6 million for 2017. The increase in research and development expenses was driven by costs incurred to advance and expand our pipeline and is primarily attributable to increased clinical trial-related costs and manufacturing costs for our development programs, as well as increased employee-related costs due to headcount growth supporting overall research and development activities.
- G&A Expenses: General and administrative expenses were $13.2 million for 2018 as compared to $12.8 million for 2017, primarily attributed to growth-related expenses.
- Net Loss: Net loss was $38.9 million for 2018 as compared to $25.5 million for 2017.
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Our Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific, whose partnerships focus on improving manufacturing processes for cell therapies. The CBMG pipeline includes preclinical compounds targeting CD20-, CD22- and B-cell maturation antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb trial in China for Rejoin® autologous Human Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial in China for AlloJoin™ (CBMG's "Off-the-Shelf" haMPC) for the treatment of KOA are ongoing. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including regulatory approval of our IND applications, our plan to configure part of our Shanghai facility with GE Healthcare's FlexFactory platform, our ability to execute on our obligations under the terms of our licensing and collaboration arrangement with Novartis, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG's reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CELLULAR BIOMEDICINE GROUP, INC. | ||||||||
CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS | ||||||||
For the Year Ended | ||||||||
2018 | 2017 | 2016 | ||||||
Net sales and revenue | $224,403 | $336,817 | $627,930 | |||||
Operating expenses: | ||||||||
Cost of sales | 135,761 | 162,218 | 860,417 | |||||
General and administrative | 13,220,757 | 12,780,483 | 11,670,506 | |||||
Selling and marketing | 308,830 | 360,766 | 425,040 | |||||
Research and development | 24,150,480 | 14,609,917 | 11,475,587 | |||||
Impairment on non-current assets | 2,914,320 | - | 4,611,714 | |||||
Total operating expenses | 40,730,148 | 27,913,384 | 29,043,264 | |||||
Operating loss | (40,505,745) | (27,576,567) | (28,415,334) | |||||
Other income: | ||||||||
Interest income | 392,328 | 133,621 | 78,943 | |||||
Other income | 1,172,879 | 1,955,086 | 132,108 | |||||
Total other income | 1,565,207 | 2,088,707 | 211,051 | |||||
Loss before taxes | (38,940,538) | (25,487,860) | (28,204,283) | |||||
Income taxes provision | (4,954) | (2,450) | (4,093) | |||||
Net loss | $(38,945,492) | $(25,490,310) | $(28,208,376) | |||||
Other comprehensive income (loss): | ||||||||
Cumulative translation adjustment | (1,079,689) | 967,189 | (743,271) | |||||
Unrealized gain (loss) on investments, net of tax | - | (240,000) | 5,300,633 | |||||
Reclassification adjustments, net of tax, in connection with other-than-temporary impairment of investments | - | - | (5,557,939) | |||||
Total other comprehensive income (loss): | (1,079,689) | 727,189 | (1,000,577) | |||||
Comprehensive loss | $(40,025,181) | $(24,763,121) | $(29,208,953) | |||||
Net loss per share: | ||||||||
Basic and diluted | $(2.20) | $(1.78) | $(2.09) | |||||
Weighted average common shares outstanding: | ||||||||
Basic and diluted | 17,741,104 | 14,345,604 | 13,507,408 | |||||
CELLULAR BIOMEDICINE GROUP, INC. | ||||
CONSOLIDATED BALANCE SHEETS | ||||
December 31, | December 31, | |||
2018 | 2017 | |||
Assets | ||||
Cash and cash equivalents | $52,812,880 | $21,568,422 | ||
Accounts receivable, less allowance for doubtful amounts of $94,868 and $10,789 as of December 31, 2018 and December 31, 2017, respectively | 787 | 202,887 | ||
Other receivables | 101,909 | 170,842 | ||
Prepaid expenses | 1,692,135 | 1,852,695 | ||
Total current assets | 54,607,711 | 23,794,846 | ||
Investments | 240,000 | 269,424 | ||
Property, plant and equipment, net | 15,193,761 | 12,973,342 | ||
Goodwill | 7,678,789 | 7,678,789 | ||
Intangibles, net | 7,970,692 | 12,419,692 | ||
Long-term prepaid expenses and other assets | 5,952,193 | 4,026,203 | ||
Total assets | $91,643,146 | $61,162,296 | ||
Liabilities and Stockholders' Equity | ||||
Liabilities: | ||||
Accounts payable | $422,752 | $225,287 | ||
Accrued expenses | 1,878,926 | 1,097,327 | ||
Taxes payable | 28,950 | 28,875 | ||
Other current liabilities | 3,836,308 | 2,324,632 | ||
Total current liabilities | 6,166,936 | 3,676,121 | ||
Other non-current liabilities | 257,818 | 183,649 | ||
Total liabilities | 6,424,754 | 3,859,770 | ||
Preferred stock, par value $.001, 50,000,000 shares authorized; none issued and outstanding as of December 31, 2018 and 2017, respectively | - | - | ||
Common stock, par value $.001, 300,000,000 shares authorized;19,120,781 and 15,615,558 issued; and 18,119,282 and 15,188,764 outstanding, as of December 31, 2018 and 2017, respectively | 19,121 | 15,616 | ||
Treasury stock at cost; 1,001,499 and 426,794 shares of common stock as of December 31, 2018 and December 31, 2017, respectively | (13,953,666) | (3,977,929) | ||
Additional paid in capital | 250,604,618 | 172,691,339 | ||
Accumulated deficit | (149,982,489) | (111,036,997) | ||
Accumulated other comprehensive loss | (1,469,192) | (389,503) | ||
Total stockholders' equity | 85,218,392 | 57,302,526 | ||
Total liabilities and stockholders' equity | $91,643,146 | $61,162,296 | ||
CELLULAR BIOMEDICINE GROUP, INC. | ||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
For the Year Ended | ||||||
December 31, | ||||||
2018 | 2017 | 2016 | ||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||
Net loss | $(38,945,492) | $(25,490,310) | $(28,208,376) | |||
Adjustments to reconcile net loss to net cash | ||||||
used in operating activities: | ||||||
Depreciation and amortization | 5,049,523 | 2,985,963 | 2,635,001 | |||
Loss on disposal of assets | 4,957 | 317 | 2,156 | |||
Stock based compensation expense | 4,826,745 | 5,345,211 | 5,452,417 | |||
Other than temporary impairment on investments | 29,424 | - | 4,611,714 | |||
Impairment on intangible assets | 2,884,896 | - | - | |||
Interest from six-month deposits with the banks | (175,479) | - | - | |||
Reversal of inventory provision | - | - | (115,391) | |||
Allowance for doubtful account | 84,622 | - | 10,163 | |||
Changes in operating assets and liabilities: | ||||||
Accounts receivable | 107,263 | (160,628) | 537,155 | |||
Other receivables | 66,108 | (467,985) | (156,672) | |||
Inventory | - | - | 514,734 | |||
Prepaid expenses | 68,435 | (812,675) | (669,598) | |||
Taxes recoverable | - | - | 150,082 | |||
Long-term prepaid expenses and other assets | (538,349) | (1,005,029) | (643,673) | |||
Accounts payable | 133,740 | (814) | (28,205) | |||
Accrued expenses | 816,936 | (118,968) | 356,420 | |||
Other current liabilities | 390,181 | 1,339,866 | (640,573) | |||
Taxes payable | 75 | - | 28,875 | |||
Other non-current liabilities | 83,416 | (208,340) | 296,036 | |||
Net cash used in operating activities | (25,112,999) | (18,593,392) | (15,867,735) | |||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
Proceeds from disposal of assets | 1,625 | - | - | |||
Withdrawing six-month deposits with the banks | 10,175,479 | - | - | |||
Putting six-month deposits with the banks | (10,000,000) | - | - | |||
Purchases of intangible assets | (196,836) | (23,734) | (56,519) | |||
Purchases of property, plant and equipment | (6,589,493) | (10,169,134) | (2,676,888) | |||
Net cash used in investing activities | (6,609,225) | (10,192,868) | (2,733,407) | |||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
Net proceeds from the issuance of common stock | 70,351,173 | 14,496,040 | 42,399,874 | |||
Proceeds from exercise of stock options | 2,738,866 | 308,371 | 885,680 | |||
Repurchase of treasury stock | (9,975,737) | (3,977,929) | - | |||
Net cash provided by financing activities | 63,114,302 | 10,826,482 | 43,285,554 | |||
EFFECT OF EXCHANGE RATE CHANGES ON CASH | (147,620) | 275,768 | (316,577) | |||
INCREASE IN CASH AND CASH EQUIVALENTS | 31,244,458 | (17,684,010) | 24,367,835 | |||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 21,568,422 | 39,252,432 | 14,884,597 | |||
CASH AND CASH EQUIVALENTS, END OF PERIOD | $52,812,880 | $21,568,422 | $39,252,432 | |||
SUPPLEMENTAL CASH FLOW INFORMATION | ||||||
Cash paid for income taxes | $4,879 | $2,450 | $6,705 | |||
Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
+1 917 717 0994
[email protected]
SOURCE Cellular Biomedicine Group
Share this article